PRTA
What one share of Prothena Corporation Public Limited holds
Pharmaceutical Preparations
Prothena Corporation plc (“Prothena” or the “Company”) is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases.
Prothena Corporation Public Limited’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.02 |
|---|---|
| Profit | −$0.82 |
| Cash and investments | $5.57 |
| Book value | $5.54 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$4.66 | — | −$3.38 | — | $10.51 |
| 2017 | — | −$4.07 | — | −$3.48 | — | $10.58 |
| 2018 | — | −$3.93 | — | −$0.71 | — | $8.10 |
| 2019 | — | −$1.95 | — | −$1.33 | — | $6.84 |
| 2020 | — | −$2.78 | — | −$2.01 | — | $4.61 |
| 2021 | $4.14 | $1.38 | — | $1.91 | — | $9.99 |
| 2022 | $1.14 | −$2.47 | — | −$2.30 | — | $11.94 |
| 2023 | $1.72 | −$2.76 | — | −$2.52 | — | $10.46 |
| 2024 | $2.51 | −$2.27 | — | −$2.79 | — | $9.05 |
| 2025 | $0.18 | −$4.53 | — | −$3.04 | — | $5.21 |